论文部分内容阅读
作者用中国吉林通化长白山药物研究所生产的抗癌新药复方天仙胶囊加~(60)钴放射治疗食管癌90例,其中病灶长短不限,性别、年龄不限,除1例外均经病理诊断证实为食管癌而无远处转移的Ⅱ—Ⅲ期病人。45例为用药加~(60)钴放射治疗组,45例为单纯~(60)钴放射治疗组。作者将两组病人治疗方案(1)服复方天仙胶囊250粒—300粒加~(60)钴半量照射DT40Gy与单纯~(60)钴半量照射DT40Gy对比。(2)服复方天仙胶囊250粒—300粒加~(60)钴半量照射DT40Gy与单纯全量~(60)钴照射DT60Gy—75Gy对比。(3)服复方天仙胶囊380粒—420粒加全量~(60)钴照射DT60Gy—75Gy与单纯~(60)钴全量照射DT60Gy—75GY对比。其结果癌肿的总缓解率是(1)用药组82.2％,对照组46％,提高36％。(2)用药组82.2％,对照组68.8％,提高13.4％。(3)用药组95.5％,对照组63.8％,提高26.7％。观察表明将复方天仙胶囊做为~(60)钴放射治疗食管癌的增敏剂很有价值。
The authors treated 90 cases of esophageal cancer with anti-cancer drug Tiantian capsules plus 60(60) cobalt radiation produced by Changbai Mountain Institute of Pharmacy, Tonghua, China. The length of the lesions was not limited, and the sex and age were not limited. All but one exception were confirmed by pathological diagnosis. Esophageal cancer with no distant metastasis in stage II-III patients. Forty-five cases were treated with cobalt plus (60) cobalt radiation therapy group and 45 cases were treated with pure cobalt (60) cobalt radiation group. The authors compared the treatment regimen of two groups of patients (1) with 250 capsules of compound Tianxian capsules (300 capsules) plus 60 (60) cobalt half doses of DT40Gy and 60 doses of cobalt (60) cobalt half dose DT40Gy. (2) serving compound Tianxian capsules 250 -300 capsules plus 60 (60) cobalt half dose DT40Gy and simple total amount of (60) cobalt irradiation DT60Gy-75Gy contrast. (3) serving compound Tianxian capsules 380 -420 capsules plus the full amount of (60) cobalt irradiation DT60Gy-75Gy and pure ~ (60) cobalt irradiation of DT60Gy-75GY contrast. The overall rate of cancer remission was (1) 82.2% in the medication group and 46% in the control group, an increase of 36%. (2) 82.2% in the medication group and 68.8% in the control group, an increase of 13.4%. (3) 95.5% of the medication group and 63.8% of the control group, an increase of 26.7%. Observations have shown that compound Tianxian capsules are valuable as sensitizers for ~(60)cobalt radiotherapy for esophageal cancer.